180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics.
Quote | 180 Life Sciences Corp Wt Pur 1/2 Com Exp 11/07/2025 (NASDAQ:ATNFW)
Last: | $0.01 |
---|---|
Change Percent: | 0.0% |
Open: | $0.0112 |
Close: | $0.01 |
High: | $0.0112 |
Low: | $0.0098 |
Volume: | 4,588 |
Last Trade Date Time: | 07/29/2024 03:00:00 am |
News | 180 Life Sciences Corp Wt Pur 1/2 Com Exp 11/07/2025 (NASDAQ:ATNFW)
MENLO PARK, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammator...
MENLO PARK, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammator...
Message Board Posts | 180 Life Sciences Corp Wt Pur 1/2 Com Exp 11/07/2025 (NASDAQ:ATNFW)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
180 Life Sciences Corp Wt Pur 1/2 Com Exp 11/07/2025 Company Name:
ATNFW Stock Symbol:
NASDAQ Market:
180 Life Sciences Corp Wt Pur 1/2 Com Exp 11/07/2025 Website:
MENLO PARK, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammator...
MENLO PARK, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammator...
MENLO PARK, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in i...